The litany of complaints against pharmaceutical companies for imposing “excessive” prices on generic drugs is growing after the European Commission decided to pursue Aspen Pharma over price rises imposed on a range of anticancer products it acquired from GSK.
Pharmaceutical companies’ pricing strategies have come under even closer antitrust scrutiny in the EU after Aspen Pharma became the subject of the European Commission’s first inquiry into “excessive” pricing in the pharmaceutical industry.
The commission said it would be looking into whether Aspen abused a dominant market position by using the...
John Crowley discussed how he prioritizes industry’s many competing challenges in a Pink Sheet interview at the BIO International Convention.
The government has explained how to navigate the UK’s regulatory and market access funding mechanisms.
The Council of the EU’s vision for the pharma reform package includes a stronger role for member states regarding the supply of medicines and the prevention of indication-stacking for orphan drugs.
